Evidence map›Paper›PMID 29071381›Full record

ReviewCurrent genetics2018

Exiting prophase I: no clear boundary.

Hideo Tsubouchi, Bilge Argunhan, Tomomi Tsubouchi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Editorial: Molecular architecture and dynamics of meiotic chromosomes.Frontiers in cell and developmental biology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Hideo TsubouchiInstitute of Innovative Research, Tokyo Institute of Technology, Tokyo, Japan. htsubouchi@bio.titech.ac.jp.ORCID http://orcid.org/0000-0003-0814-8432
Bilge ArgunhanInstitute of Innovative Research, Tokyo Institute of Technology, Tokyo, Japan.
Tomomi TsubouchiNational Institute for Basic Biology, Okazaki, Japan.
Tokyo Institute of Technology · JPNational Institute for Basic Biology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The meiotic cell cycle provides a unique model to study the relationship between recombinational DNA repair and the cell cycle, since homologous recombination, induced by programmed DNA double-strand breaks (DSBs), is integrated as an essential step during meiosis. The pachytene checkpoint, which is situated towards the end of meiotic prophase I, coordinates homologous recombination and cell cycle progression, similar to the DNA damage checkpoint mechanisms operating in vegetative cells. However, there are a number of features unique to meiosis, making the system optimized for the purpose of meiosis. Our recent work highlights the involvement of three major cell cycle kinases, Dbf4-dependent Cdc7 kinase, Polo kinase and CDK, in coordinating homologous recombination and the meiotic cell cycle. In this review, we will discuss the unique interplay between meiotic cell cycle control and homologous recombination during meiosis I.

Indexed as

Cell Cycle ProteinsDNA-Binding ProteinsDNA Breaks, Double-StrandedDNA DamageMeiosisMeiotic Prophase IPhosphorylationProtein Serine-Threonine KinasesSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsCDC7 protein, S cerevisiaeCell Cycle ProteinsDbf4 protein, S cerevisiaeDNA-Binding ProteinsProtein Serine-Threonine KinasesSaccharomyces cerevisiae ProteinsBudding yeastCDKDDKHomologous recombinationPolo kinaseThe cell cycleThe synaptonemal complex

Identifiers

PMID29071381
OpenAlexW2766729438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.